REG - EKF Diagnostics Hldg - Appointment of CEO

EKF Diagnostics HoldingsAnnouncement

25/03/2025 07:15

For best results when printing this announcement, please click on link below:
https://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20250325:nRSY9656Ba&default-theme=true

RNS Number : 9656B  EKF Diagnostics Holdings PLC  25 March 2025

EKF Diagnostics Holdings plc

("EKF" or the "Company")

 

Appointment of CEO

 

EKF Diagnostics Holdings plc (AIM: EKF), the AIM-listed global diagnostics
business, announces the appointment of Gavin Jones as Chief Executive Officer
and to the EKF Board, with immediate effect. Gavin previously served as Chief
Product Officer at EKF and has extensive industry experience in Analytical
Chemistry and Diagnostics. Julian Baines will remain as Executive Chair for
the foreseeable future.

 

In his role as Chief Product Officer, Gavin led the Product Management,
R&D, Marketing and Regulatory departments, bringing new and updated
products to market, delivering on enhanced connectivity solutions and
user-friendly design to meet evolving customer needs. Before joining EKF in
2013, Gavin held a Product Management role at Biotage AB and analyst positions
at PCI (then trading as Penn Pharma) and the Forensic Science Service,
initially starting out in the laboratory but quickly transitioning to product
strategy and innovation. His expertise spans commercial strategy, business
development, and product lifecycle management, contributing to significant
growth in global healthcare markets.

 

Gavin holds a BSc (Hons) Forensic and Biomolecular Science degree from
Liverpool John Moores University and has a track record of driving product
innovation and operational excellence. Gavin is committed to expanding EKF's
point-of-care solutions and strengthening its market presence in Life
Sciences.

 

 

Julian Baines, Executive Chair of EKF, commented: "I'm delighted that Gavin
Jones is taking on the role as Chief Executive Officer and joining the Board.
Gavin has over twenty years of experience in Point-of-Care and Life Sciences
and has been instrumental in driving the commercial success of many of our
products. Many shareholders have met Gavin over the last year or so as he's
become more and more involved in the senior leadership team. Gavin has
ambitious plans for delivering sustainable growth and unlocking the unrealised
potential that our core products and service hold. We have an exciting
opportunity to increase our commercial investment to drive organic growth and
I'm delighted that Gavin will lead that process."

 

Additional Disclosures Required under the AIM Rules for Companies

Gavin Joseph Jones (aged 44) holds no shares in the Company and has held no
directorship or partnerships in the past five years.

 

Save as disclosed above, there is no further information to be disclosed in
respect of the above appointment pursuant to Rule 17 and Schedule 2 paragraph
(g) of the AIM Rules for Companies.

 

 

 EKF Diagnostics Holdings plc                                www.ekfdiagnostics.com (http://www.ekfdiagnostics.com)
 Julian Baines, Executive Chair                               via Walbrook PR

 Singer Capital Markets (Nominated Adviser & Broker)                                       Tel: +44 (0)20 7496 3000
 Phil Davies / Oliver Platts

 Walbrook PR Limited              Tel: +44 (0)20 7933 8780 or ekf@walbrookpr.com (mailto:ekf@walbrookpr.com)
 Paul McManus / Alice Woodings    Mob: +44 (0)7980 541 893 / +44 (0)7407 804 654

 

 

 

About EKF Diagnostics Holdings plc (www.ekfdiagnostics.com
(http://www.ekfdiagnostics.com) )

 

EKF is an AIM-listed global diagnostics business focussed on:

 

 ●    Point-of-Care analysers in the key areas of Hematology and Diabetes
 ●    Life Sciences services provide specialist manufacture of enzymes and custom
      products for use in diagnostic, food and industrial applications.

 

EKF has headquarters in Penarth (near Cardiff) and operates five manufacturing
sites across the US and Germany, selling into over 120 countries world-wide.

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
 or visit
www.rns.com (http://www.rns.com/)
.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
.   END  BOAPPUQGWUPAPPC